Targeting gut microbiota in hepatocellular carcinoma: probiotics as a novel therapy

Murphy L. Y. Wan, Hani El-Nezami

Research output: Contribution to journalArticlepeer-review


Hepatocellular carcinoma (HCC), the most common primary liver cancer, is one of the dreaded complications of chronic liver disease. Recent experimental and clinical studies have revealed that the alteration of gut-liver axis plays a pivotal role in the onset of chronic liver diseases, including HCC. Altered gut microbiota and endotoxemia are increasingly recognized as critical components in promoting the progression of chronic liver diseases to HCC. Probiotics have been suggested as a novel, safe and cost-effective approach to prevent or treat HCC. Mechanisms by which probiotics exerts their anti-cancer effects include their ability to bind carcinogens, modulation of gut microbiota, improvement of intestinal barrier function, and immunomodulation. This review summarizes the literature findings of the changes in gut microbiota linked to HCC, and discusses the possible therapeutic implications of probiotics for HCC.
Original languageEnglish
Pages (from-to)11-20
Number of pages10
JournalHepatoBiliary Surgery and Nutrition
Issue number1
Publication statusPublished - 1 Feb 2018


  • endotoxemia
  • gut-liver axis
  • gut microbiota
  • hepatocellular carcinoma (HCC)
  • probiotics


Dive into the research topics of 'Targeting gut microbiota in hepatocellular carcinoma: probiotics as a novel therapy'. Together they form a unique fingerprint.

Cite this